Year-end Sale % OFF 
Abstract
The human tumor phenotype referred to as MSI (Microsatellite Instability) is associated with inactivating alterations in MMR genes (Mismatch Repair). MSI was first observed in inherited malignancies associated with Lynch syndrome and later in sporadic colon, gastric and endometrial cancers. MSI tumors develop through a distinctive molecular pathway characterized by genetic instability in numerous microsatellite DNA repeat sequences throughout the genome. In this article, french researchers and physicians who have been recently awarded by the Fondation de France (Jean and Madeleine Schaeverbeke prize) make a sum of their activity in the MSI cancer field for more than 20 years. Their findings have greatly contributed to increase our knowledge of this original cancer model, laying the foundation for a personalized medicine of MSI tumors.
Highlights
MSI was first observed in inherited malignancies associated with
MSI tumors develop through a distinctive molecular pathway characterized by genetic instability
french researchers and physicians who have been recently awarded by the Fondation de France
Summary
> L’instabilité des séquences répétées du génome (appelées microsatellites) est une conséquence de l’inactivation fonctionnelle du système de réparation des erreurs produites au cours de la réplication de l’ADN (système MMR, mismatch repair). Cet article propose une synthèse des travaux dédiés à l’étude des cancers MSI menés par des chercheurs et médecins français récompensés par le prix Jean et Madeleine Schaeverbeke de la Fondation de France. Ils ont trait à la mise au point de méthodes diagnostiques ayant permis d’identifier ce phénotype tumoral chez l’homme, à la mise en évidence de facteurs de risque favorisant leur émergence dans la population, à la caractérisation de mécanismes physiopathologiques sous-jacents impliqués dans l’initiation et la progression tumorale MSI, à l’identification de marqueurs d’intérêt pronostique ou même théranostique dans ces cancers, ou encore à l’étude de l’impact des MSI sur la réponse à la chimiothérapie (Figure 1).
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
